Single-nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene may have clinical implications. The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX). The study included 72 patients with mCRC. Genomic DNA was isolated from whole blood, and SNPs were analyzed by PCR. SNPs were correlated with response and progression-free survival (PFS). Haplotypes were estimated using the PHASE program. Response was observed in 21% of the patients with the À2578 CA genotype compared with 59% of the patients with CC þ AA, P ¼ 0.002, in 26% of the patients with the À460 CT genotype compared with 57% with CC þ TT, P ¼ 0.01, and in 27% of the patients with the þ 405 GC genotype compared with 54% with GG þ CC, P ¼ 0.02. Two SNPs were significantly related to PFS. A haplotype with a significant relationship to response was identified. The results demonstrated obvious relationships between genetic variations in the VEGF-A gene and response to first-line XELOX in patients with mCRC, which translated to a significant difference in PFS. The results call for validation in a larger cohort of patients.
Introduction
The prediction of response to anticancer therapy is of outmost importance in clinical oncology, and a better selection of patients is a prerequisite for more effective treatments. Furthermore, issues like quality of life and economy should also be remembered.
Genetic variations in genomic DNA from normal cells, easily accessible in blood samples, are stable molecular markers compared with genetic variations in the tumor DNA. Such genetic variations therefore represent attractive candidate markers for the prediction of response to chemotherapy. Single-nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene have been associated with an influence on VEGF-A gene expression levels and the prognosis of colorectal cancer (CRC). [1] [2] [3] Evidence suggests that VEGF-A is essential for the development of especially the immature microvessels lacking pericyte coverage. 4 Furthermore, the presence or absence of VEGF-A influences the structure and function of blood vessels, including the delivery of chemotherapy to the tumor cells. [5] [6] [7] Thus SNPs in the VEGF-A gene may influence the delivery of chemotherapy to the cancer cells in different ways, and may consequently hold predictive information related to response to chemotherapy.
Besides the KRAS mutational status, no predictive biomarkers have so far successfully been implemented in the clinic to individualize the treatment of patients with metastatic colorectal cancer (mCRC). Some predictive markers related to preoperative chemoradiation for patients with rectal cancers have been suggested, 8, 9 and in relation to chemotherapy for mCRC, [10] [11] [12] [13] [14] [15] [16] but most of them are awaiting validation in prospective trials.
In regard to combined chemotherapy and anti-VEGF-A treatment, a study from 2008 by Schneider et al. 17 examined the relationship between several SNPs in the VEGF system and the efficacy of paclitaxel plus bevacizumab in 363 breast cancer patients. The results indicated a relationship between the VEGF-A À2578 AA genotype and the VEGF-A À1154 A allele and improved overall survival (OS) for the combination arm receiving paclitaxel and bevacizumab. This was the first trial to identify SNPs in the VEGF-A gene as potential predictive biomarkers in relation to anti-VEGF-A therapy combined with chemotherapy.
In most trials, bevacizumab is given in combination with chemotherapy, and consequently it is difficult to decide whether a biomarker is restricted to chemotherapy, bevacizumab or the combination of both. It is therefore important to analyze the potential predictive markers in patients given chemotherapy only as a prerequisite for prediction of effect in combination with bevacizumab.
The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs in patients with mCRC treated with first-line capecitabine and oxaliplatin (XELOX).
Materials and methods

Study population, sampling and treatment regimen
The study included 72 patients with mCRC, histologically verified at the Department of Clinical Pathology, Vejle Hospital, Denmark, in the period from December 2004 to February 2008. Pretreatment examination consisted of standard hematological parameters and a computed tomography (CT) scan of the thorax and abdomen. The study was approved by the Regional Scientific Ethical Committee for Southern Denmark according to Danish law, and informed consent was obtained from all patients enrolled in the study.
Blood samples for genetic analysis were collected independent of treatment initiation.
All patients received the same treatment (XELOX), which consisted of a 2-h intravenous infusion of oxaliplatin 130 mg m -2 on day 1 followed by oral capecitabine 1000 mg m -2 twice daily on days 1 through 14 (28 doses) of a 21-day cycle. Treatment was continued until disease progression or unacceptable toxicity.
Analysis of SNP
Genomic DNA was isolated from whole blood by the NucleoSpin Tissue method according to the user manual (Machery-Nagel, Düren, Germany, May 2005/Rev.04) (http:// www.bioke.com/blobs/Macherey-Nagel/GenomicDNABlood_ R04.pdf).
The PCR analysis was performed using the ABI PRISM 7900 HT fast real-time PCR system (Applied Biosystem, Foster City, CA, USA). Commercial assays (also from Applied Biosystem) were used for the analyses of the VEGF-A SNPs. Assay number and the approximate length of the amplification products (estimated by gel electrophoresis) are shown as a footnote in Table 1 . The four SNPs analyzed were VEGF-A À2578 C/A SNP (rs699947), VEGF-A À460 C/T SNP (rs833061), VEGF-A 405 G/C SNP (rs2010963) and the VEGF-A 936 C/T SNP (rs3025039).
Evaluation and tumor response criteria
The response according to RECIST (version February 2000) was assessed every 9 weeks with clinical and radiological examination using CT scan of the thorax and abdomen. Responding patients were classified as having either complete response or partial response (PR). Patients with stable disease or progressive disease were defined as nonresponders. A radiologist evaluated the CT scans and two independent oncologists verified the response for all 
Statistical analysis
The genotypes for each SNP were analyzed both as a threegroup and a two-group categorical variable, and Fisher's exact test was used for comparison with response and patient characteristics. The w 2 statistics were used to test for HardyWeinberg equilibrium. The haplotypes and their frequecies were estimated using the PHASE program, version 2.1 (Matthew Stephens, Department of Statistics, University of Chicago, Chicago, IL, USA) (http://depts.washington.edu/ ventures/UW_Technology/Express_Licenses/PHASEv2.php), which implements a Bayesian statistical method for reconstructing haplotypes from genotype data. 18, 19 Progression-free survival (PFS) was defined as the time from start of treatment until the first documented tumor progression or death. The OS was defined as the time from start of treatment until death. Survival curves were illustrated according to the Kaplan-Meier method and the log-rank test was used to test for differences between the groups. The Cox regression method was used for multivariate PFS analysis. All statistical calculations were carried out using the NCSS statistical software (NCSS Statistical Software, Kaysville, UT, USA, version 2007). P-values o0.05 were considered significant, and all tests were two sided.
Results
Patient characteristics
Patient characteristics are listed in Table 2 together with response rates and PFS. The median age was 62 years (range 42-77 years). Altogether, 46 of the patients were diagnosed with colon cancer and 26 with rectal cancer. The median observation time was 20.3 months (range 12.4-36.7 months) and in this period 55 patients died and 16 progressed. Table 1 shows the distribution of genotypes for the SNPs. They all followed the Hardy-Weinberg equilibrium.
No significant associations were detected between the genotypes of the SNPs and patient characteristics (data not shown).
No patients achieved complete response, 30 patients achieved partial response (42%), 34 patients had stable disease (47%) and 8 had progressive disease (11%). The median PFS was 6.9 months (range 0.3-16.1 months) and the median OS was 18.1 months (range 0.3-36.7 months). Five patients were excluded from the final analysis comparing SNP status and PFS because of change to second-line treatment before progression (and as a consequence they achieved a higher PFS) and one patient because of noncancer-specific death only 8 days after treatment initiation.
The predictive value of VEGF-A SNPs in relation to XELOX Table 3 shows the relationship between treatment response and SNP status. The VEGF-A À2578 CA, À460 CT and 405 GC genotypes were related to inferior response rates compared with the corresponding homozygous genotypes. This was further demonstrated when comparing patients heterozygous in all three SNPs with the remaining patients. Response was only seen in 5 of 27 (19%) compared with 25 of 45 (56%), P ¼ 0.003. Table 4 shows the results of the univariate survival analysis according to SNP status. Especially the À2578 C/T and the 405 G/C SNPs demonstrated a significant relationship with PFS. The relationship between PFS and the various genotypes of all four SNPs is illustrated in Figure 1 . No significant difference on OS was seen according to the SNP genotypes (data not shown).
PFS and VEGF-A SNPs
When performing a multivariate analysis, the VEGF-A SNPs and the patient characteristics showing a trend toward a difference in PFS in the univariate analysis were included in the Cox regression model. Table 5 shows the results of the final multivariate PFS analysis, which included the six most relevant markers. None of the markers were significantly associated with PFS, but prior operation, the VEGF-A 405 GC and the VEGF-A 936 CC genotypes showed a trend toward a difference in PFS.
Haplotype analysis
Haplotype analysis was performed to evaluate the combined effect of the four SNPs on treatment response. The nucleotide at position 1 refers to the À2578 SNP, position 2 to the À460 SNP, position 3 to the 405 SNP and the last position refers to the 936 SNP. Eight of the sixteen possible haplotypes were found in frequencies over 0.5% (ACGC, 43.4%; CTCC, 27.0%; CTGC, 9.4%; ACGT, 9.4%; CTCT, 6.9%; CTGT, 2.5%; ATGC, 0.7%; CCGC, 0.6%). Table 6 shows the distribution of haplotypes according to response.
The CTCC and CTCT haplotypes showed a negative association with response. The response rate was significantly lower in the patients with the CTCC/CTCT haplotypes (12 of 41) (29%) compared with the remaining patients (18 of 31) (58%), P ¼ 0.02 (Fisher's exact test).
Discussion
The literature regarding predictive biomarkers with relation to 5-fluorouracil and oxaliplatin treatment regimens for patients with mCRC is inconclusive, and primarily based on retrospective studies. [11] [12] [13] [14] [15] [16] SNPs in the VEGF-A gene might influence the delivery of chemotherapy to the cancer cells and may consequently hold predictive information in relation to response. [4] [5] [6] [7] This problem motivated this study. The SNPs were chosen because of their frequencies and because previous reports have described functional as well as prognostic importance in different malignancies. 1, 2, 17, [20] [21] [22] [23] [24] The genotype frequencies regarding these SNPs in our study is in agreement with those reported in the literature on CRC patients. 1, 23, 25, 26 Any minor variation could be explained by sample sizes and differences in ethnicity. All SNPs were in Hardy-Weinberg equilibrium. In this study, we demonstrated a relationship between three SNPs in the VEGF-A gene and the response to first-line XELOX for patients with mCRC, namely, that the VEGF-A À2578 CA, À460 CT and 405 GC genotypes all associated with inferior response rates compared with the The VEGF-A À2578 C-allele has been associated with VEGF-A production in vitro 28 and the À2578 CA genotype with increased VEGF-A protein expression in patients with nonsmall cell lung cancer. 29 The VEGF-A À460 C-allele has been associated with increased VEGF-A gene expression in CRC tissue 3 and with increased protein concentration of VEGF-A in normal colorectal tissue. 30 Finally, the VEGF-A 405 CC genotype has been associated with increased serum VEGF-A in healthy individuals 31 and the 405 G-allele with increased protein concentration of VEGF-A in normal colorectal tissue and with the production of VEGF-A in vitro. 30, 32 Together with the results from this study, these results all support functionality of these SNPs in the VEGF-A gene.
The VEGF-A 936 C/T SNP showed no relationship with response to chemotherapy in this study. This could be explained by the location of the SNP in the 3 0 -untranslated region (3 0 UTR) of the gene compared with the location of the three other SNPs in the promoter and the 5 0 UTR of the gene. Genetic variations in the 3 0 UTR of the gene could still be of functional importance though, which is supported by two previous reports that demonstrated an association between the VEGF-A 936 T-allele and lower plasma VEGF-A concentrations in healthy individuals. 33, 34 The results from this study are not easy to explain but the VEGF-A À2578 CA, À460 CT and 405 GC genotypes may lead to conformational changes of the VEGF-A dimer resulting in reduced activity. Diminished binding capacity of VEGF-A to its receptors could also be a consequence. Such changes could be a possible explanation to the low response rates, but several other mechanisms may be involved.
The inferior response rates in the patients with VEGF-A À2578 CA and VEGF-A 405 GC genotypes in our study were translated to significant differences in PFS. The VEGF-A 405 GC genotype together with the VEGF-A 936 CC genotype demonstrated a marginal significant relationship to PFS in multivariate analysis. The VEGF-A 936 C/T SNP showed no relationship with response but a possible prognostic influence of this SNP can not be excluded. Kim et al.
1 examined the prognostic influence of VEGF-A SNPs in 445 Korean patients operated for CRC. The results suggested that the 35 reported that the VEGF-A À2578 AA, 405 CC and 936 TT genotypes were related to significantly lower OS in 312 Greek patients with CRC. Differences in disease stages, sample sizes and ethnicity could probably explain some of these discrepancies.
We performed a subgroup analysis testing for differences in the observed SNP associations with clinical outcome for rectal and colon cancers separately but found no differences (data not shown). The smaller sample size, especially in regard to patients with rectal cancer does, however, strongly hamper the statistical analysis.
The similar findings for three of the four SNPs in this study suggest that the associations with treatment response might be related to specific haplotypes rather than individual effects of the SNPs. One might also get the impression from Table 3 that the locus in the gene responsible for this relationship with response is located closest to the À2578 C/T SNP. Consequently, we performed a haplotype analysis to evaluate the combined effect of the four SNPs on treatment response. The CTCC and CTCT haplotypes were associated with inferior response rates. ACGC, the most common haplotype (43%), showed no association with response, but its high frequency gives an explanation for the results seen at the genotype level. The haplotype combinations for a large fraction of the nonresponding patients were CTCC, ACGC or CTCT, ACGC. This corresponds to the À2578 CA, À460 CT and 405 GC genotypes in the first three SNPs independent of the nucleotide on the fourth position, the 936 C/T SNP, which did not show any association to response at the genotype level. These findings suggest that the inferior response rates demonstrated in more than half of these patients (41/72) (57%) could be explained by a mutation in the CTC'X' haplotype independent of the 936 C/T SNP.
This study has its limitations. First of all, 72 patients is a rather small sample size and the results should be considered preliminary and validation in another cohort of patients is of course necessary for further evidence. The patient cohort is heterogeneous consisting of patients with colon and rectal cancers, and the possible effect of this on the results is difficult to asses in a cohort of this size. Finally, we can not specify whether it was the response to capecitabine, oxaliplatin or the combination of both that seemed to be related to SNPs in the VEGF-A gene in this study.
In conclusion, this study demonstrated an obvious relationship between SNPs in the VEGF-A gene and response to first-line XELOX in patients with mCRC, which translated to a significant difference in PFS. Furthermore, we identified the haplotype most likely to be responsible for this effect. The findings call for validation in a larger cohort of patients. Abbreviation: XELOX, capecitabine and oxaliplatin.
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